AB Science S.A
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyo… Read more
AB Science S.A (ABSCF) - Net Assets
Latest net assets as of June 2025: $-27.32 Million USD
Based on the latest financial reports, AB Science S.A (ABSCF) has net assets worth $-27.32 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.22 Million) and total liabilities ($48.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-27.32 Million |
| % of Total Assets | -128.78% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1892.43 |
AB Science S.A - Net Assets Trend (2009–2024)
This chart illustrates how AB Science S.A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AB Science S.A (2009–2024)
The table below shows the annual net assets of AB Science S.A from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-23.75 Million | -13.06% |
| 2023-12-31 | $-21.01 Million | +41.10% |
| 2022-12-31 | $-35.67 Million | -53.76% |
| 2021-12-31 | $-23.20 Million | -18.67% |
| 2020-12-31 | $-19.55 Million | +27.13% |
| 2019-12-31 | $-26.83 Million | -79.31% |
| 2018-12-31 | $-14.96 Million | -239.38% |
| 2017-12-31 | $10.73 Million | +328.16% |
| 2016-12-31 | $-4.71 Million | +72.74% |
| 2015-12-31 | $-17.26 Million | -10.06% |
| 2014-12-31 | $-15.68 Million | -4698.53% |
| 2013-12-31 | $341.00K | -93.04% |
| 2012-12-31 | $4.90 Million | -36.63% |
| 2011-12-31 | $7.73 Million | -47.70% |
| 2010-12-31 | $14.78 Million | +1320.08% |
| 2009-12-31 | $1.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AB Science S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $579.00K | % |
| Other Comprehensive Income | $-295.85 Million | % |
| Other Components | $271.52 Million | % |
| Total Equity | $-23.75 Million | 100.00% |
AB Science S.A Competitors by Market Cap
The table below lists competitors of AB Science S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
APEX International Financial Engineering Res & Tech Co Ltd
TWO:5210
|
$39.90 Million |
|
Nanexa AB
ST:NANEXA
|
$39.92 Million |
|
Lake Shore Bancorp Inc
NASDAQ:LSBK
|
$39.93 Million |
|
DENARIUS METALS CORP.
F:T7C0
|
$39.94 Million |
|
Elementos Ltd
AU:ELT
|
$39.89 Million |
|
DanCann Pharma A/S
PINK:DCPXF
|
$39.87 Million |
|
Clipper Realty Inc
NYSE:CLPR
|
$39.85 Million |
|
Black Mammoth Metals Corporation
PINK:LQRCF
|
$39.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AB Science S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -21,010,000 to -23,754,000, a change of -2,744,000.
- Net loss of 7,831,000 reduced equity.
- Other comprehensive income decreased equity by 8,400,000.
- Other factors increased equity by 13,487,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.83 Million | -32.97% |
| Other Comprehensive Income | $-8.40 Million | -35.36% |
| Other Changes | $13.49 Million | +56.78% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares AB Science S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | $0.03 | $1.57 | x |
| 2010-12-31 | $0.49 | $1.57 | x |
| 2011-12-31 | $0.25 | $1.57 | x |
| 2012-12-31 | $0.15 | $1.57 | x |
| 2013-12-31 | $0.01 | $1.57 | x |
| 2014-12-31 | $-0.48 | $1.57 | x |
| 2015-12-31 | $-0.50 | $1.57 | x |
| 2016-12-31 | $-0.13 | $1.57 | x |
| 2017-12-31 | $0.30 | $1.57 | x |
| 2018-12-31 | $-0.40 | $1.57 | x |
| 2019-12-31 | $-0.68 | $1.57 | x |
| 2020-12-31 | $-0.44 | $1.57 | x |
| 2021-12-31 | $-0.49 | $1.57 | x |
| 2022-12-31 | $-0.76 | $1.57 | x |
| 2023-12-31 | $-0.42 | $1.57 | x |
| 2024-12-31 | $-0.45 | $1.57 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AB Science S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -730.50%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-358.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -779.06% | -2566.46% | 0.02x | 13.53x | $-8.21 Million |
| 2010 | -64.19% | -1034.79% | 0.03x | 1.99x | $-10.97 Million |
| 2011 | -124.84% | -874.18% | 0.04x | 3.81x | $-10.42 Million |
| 2012 | -224.23% | -819.78% | 0.04x | 6.12x | $-11.47 Million |
| 2013 | -4284.75% | -755.87% | 0.04x | 127.96x | $-14.65 Million |
| 2014 | 0.00% | -767.60% | 0.07x | 0.00x | $-14.54 Million |
| 2015 | 0.00% | -1169.70% | 0.07x | 0.00x | $-24.99 Million |
| 2016 | 0.00% | -1836.60% | 0.04x | 0.00x | $-27.23 Million |
| 2017 | -252.65% | -1559.63% | 0.03x | 4.71x | $-28.20 Million |
| 2018 | 0.00% | -1532.10% | 0.08x | 0.00x | $-24.56 Million |
| 2019 | 0.00% | -1384.28% | 0.09x | 0.00x | $-19.06 Million |
| 2020 | 0.00% | -950.41% | 0.05x | 0.00x | $-13.09 Million |
| 2021 | 0.00% | -900.00% | 0.08x | 0.00x | $-12.14 Million |
| 2022 | 0.00% | -1421.19% | 0.04x | 0.00x | $-10.05 Million |
| 2023 | 0.00% | -1235.57% | 0.04x | 0.00x | $-9.88 Million |
| 2024 | 0.00% | -730.50% | 0.05x | 0.00x | $-5.46 Million |
Industry Comparison
This section compares AB Science S.A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $608,196,792
- Average return on equity (ROE) among peers: -472.34%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AB Science S.A (ABSCF) | $-27.32 Million | -779.06% | N/A | $39.89 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |